Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Imugene ( (AU:IMU) ).
Imugene Limited has applied to the ASX for quotation of a new class of options, comprising 15,077,309 quoted options exercisable at $0.18 and expiring on 30 April 2027, issued on 24 April 2026. The move adds a significant tranche of listed derivatives to Imugene’s capital structure, potentially broadening investor participation and providing additional avenues for capital raising as the biotech advances its oncology pipeline.
The options quotation may enhance trading liquidity in Imugene securities and offer existing and prospective shareholders leveraged exposure to the company’s future performance. By expanding its listed security types, Imugene underscores its continued engagement with capital markets to support ongoing development activities in the competitive immuno-oncology sector.
The most recent analyst rating on (AU:IMU) stock is a Buy with a A$0.82 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an Australia-based biotechnology company listed on the ASX under the code IMU. The company focuses on developing immuno-oncology therapies aimed at treating various cancers, positioning itself within the global biopharmaceutical and cancer therapeutics market.
Average Trading Volume: 1,591,716
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$48.37M
Find detailed analytics on IMU stock on TipRanks’ Stock Analysis page.